Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse
Status:
Not yet recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
This is a phase II interventional trial to evaluate if the use of ponatinib, with or without
chemotherapy, can induce a molecular remission in MRD-positive patients, in patients in
hematologic and extra-hematologic relapse and in the few patients who never achieved an
hematologic remission after whatever prior treatment.